S&P 500
5,888.55
-0.6%
-$32.99
DJI
42,098.70
-0.6%
-$244.95
NASDAQ
19,100.94
-0.5%
-$98.23
Bitcoin
107,495.00
-1.4%
-1,565.38
AAPL
$200.40
+0.1%
+$0.19
AMZN
$204.64
-0.7%
-$1.38
GOOG
$173.28
-0.4%
-$0.70
META
$643.48
+0.2%
+$1.16
MSFT
$457.40
-0.7%
-$3.28
NVDA
$135.14
-0.3%
-$0.36
TSLA
$356.97
-1.6%
-$5.92
Citius Oncology (NASDAQ: CTOR)
$0.92
(3.0%)
$0.03
Price as of May 28, 2025, 10:58 a.m. ET
Citius Oncology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Citius Oncology Company Info
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.